Endokrinoloji Poliklinik Hastalarında Cinsiyet, Menopoz Durumu ve Glukoz Toleransının Osteokalsin Seviyeleri Üzerindeki Etkileri: Bir Vaka-Kontrol Çalışması

Abstract

Amaç: Bu çalışmada, endokrinoloji poliklinik hastalarında cinsiyet, menopoz durumu ve glukoz toleransına göre total ve karboksile olmayan osteokalsin düzeylerinin değerlendirilmesi amaçlandı. Gereç ve Yöntemler: Oral glukoz tolerans testi (OGTT) bulguları olan toplam 178 endokrinoloji poliklinik hastası dahil edildi. Antropometri verileri [vücut kütle indeksi (VKİ), bel çevresi (cm), vücut yağ yüzdesi (BFP) ve yağ kütlesi], glisemik parametreler [açlık kan şekeri (FBG), insülin), C-peptid, HbA1c ve insülin direnç direnci (HOMA-IR)], kan lipidleri ve serum osteokalsin (OCN) seviyeleri [toplam osteokalsin (tOCN) ve karboksile olmayan osteokalsin (uOCN)] cinsiyet, menopoz durumu ve glukoz tolerans durumu ile karşılaştırıldı.Bulgular: Cinsiyet ve menopoz durumu ile ilgili olarak tOCN ve uOCN düzeylerinde anlamlı bir farklılık kaydedilmedi. Glukoz toleransı normal olan hastalarda (p <0.05) ve premenopozal kadınlarda (p <0.05) tOCN ile VKİ, bel çevresi, BFP ve yağ kütlesi arasında negatif korelasyon vardı. Ayrıca tOCN, prediyabetli hastalarda BFP ve yağ kütlesi ile negatif (p <0.05), prediyabet grubunda açlık insülin düzeyleri ve HOMA-IR ile pozitif korelasyon gösterdi (p <0.05). Sonuç: Bulgularımız cinsiyet, menopoz durumu veya glukoz toleransı açısından tOCN ve uOCN düzeylerinde anlamlı bir farklılık göstermedi. İnsanlarda OCN-glukoz homeostaz bağlantısının daha sınırlı bir rolü ve karmaşık düzenlenmesi olasılığı dikkate alınmalıdır. OCN-glukoz homeostaz mekanizmasının kanıtlanabilmesi için daha geniş çaplı çalışmalara ihtiyaç vardır.

Keywords

• Osteokalsin
• Diyabetes mellitus
• Tip 2
• Şişmanlık
• Glukoz tolerans testi
• Menopoz

The Effects of Sex, Menopausal Status, and Glucose Tolerance on Osteocalcin Levels in Endocrinology Outpatients: A Case-Control Study

Abstract

menopausal status, and glucose tolerance in endocrinology outpatients. Material and Methods: A total of 178 endocrinology outpatients with oral glucose tolerance test (OGTT) findings were included. Data on anthropometrics [body mass index (BMI), waist circumference (cm), body fat percentage (BFP), and fat mass], glycemic parameters [fasting blood glucose (FBG), insulin), C-peptide, HbA1c, and insulin resistance (HOMA-IR)], blood lipids, and serum osteocalcin (OCN) levels [total osteocalcin (tOCN) and uncarboxylated osteocalcin (uOCN)] were compared with sex, menopausal status, and glucose tolerance status. Results: No significant difference was noted in the tOCN and uOCN levels concerning gender and menopausal status. tOCN was negatively correlated with BMI, waist circumference, BFP, and fat mass in patients with normal glucose tolerance (p<0.05) and premenopausal women (p<0.05). Besides, tOCN was negatively correlated with BFP and fat mass in patients with prediabetes (p<0.05) and positively correlated with fasting insulin levels and HOMA-IR in the prediabetes group (p<0.05). Conclusion: Our findings revealed no significant difference in tOCN and uOCN levels regarding sex, menopausal status or glucose tolerance. The likelihood of a more limited role and complex regulation of OCN-glucose homeostasis link in humans should be considered.

Keywords

• Osteocalcin
• Diabetes Mellitus
• Type 2
• Adiposity
• Glucose Tolerance Test
• Menopause

References

1. 1. Ferron M, Lacombe J. Regulation of energy metabolism by the skeleton: osteocalcin and beyond. Arch Biochem Biophys. 2014;561:137–146.
2. 1. Ferron M, Lacombe J. Regulation of energy metabolism by the skeleton: osteocalcin and beyond. Arch Biochem Biophys. 2014;561:137–146.
3. 2. Liatis S, Sfikakis PP, Tsiakou A, Stathi C, Terpos E, Katsilambros N, Makrilakis K. Baseline osteocalcin levels and incident diabetes in a 3-year prospective study of high-risk individuals. Diabetes Metab. 2014;40(3):198–203.
4. 2. Liatis S, Sfikakis PP, Tsiakou A, Stathi C, Terpos E, Katsilambros N, Makrilakis K. Baseline osteocalcin levels and incident diabetes in a 3-year prospective study of high-risk individuals. Diabetes Metab. 2014;40(3):198–203.
5. 3. Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, Ducy P, Karsenty G. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell. 2010;142(2):296–308.
6. 3. Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, Ducy P, Karsenty G. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell. 2010;142(2):296–308.
7. 4. Zoch ML, Clemens TL, Riddle RC. New insights into the biology of osteocalcin. Bone. 2016;82:42–49.
8. 4. Zoch ML, Clemens TL, Riddle RC. New insights into the biology of osteocalcin. Bone. 2016;82:42–49.

9. 5. Mizokami A, Kawakubo-Yasukochi T, Hirata M. Osteocalcin and its endocrine functions. Biochem Pharmacol. 2017;132:1–8.
10. 5. Mizokami A, Kawakubo-Yasukochi T, Hirata M. Osteocalcin and its endocrine functions. Biochem Pharmacol. 2017;132:1–8.
11. 6. Accard JL, Patte F, Combes F, Sorin C, Gaillard F, Garel L, Lafon D. [Spontaneous pneumothorax. Clinical study, meteorological correlations, course and treatment]. Rev Tuberc Pneumol (Paris). 1972;36(3):431–446.
12. 6. Accard JL, Patte F, Combes F, Sorin C, Gaillard F, Garel L, Lafon D. [Spontaneous pneumothorax. Clinical study, meteorological correlations, course and treatment]. Rev Tuberc Pneumol (Paris). 1972;36(3):431–446.
13. 7. Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates β cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci. 2008;105(13):5266–5270.
14. 7. Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates β cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci. 2008;105(13):5266–5270.
15. 8. Kanazawa I, Yamaguchi T, Tada Y, Yamauchi M, Yano S, Sugimoto T. Serum osteocalcin level is positively associated with insulin sensitivity and secretion in patients with type 2 diabetes. Bone. 2011;48(4):720–725.
16. 8. Kanazawa I, Yamaguchi T, Tada Y, Yamauchi M, Yano S, Sugimoto T. Serum osteocalcin level is positively associated with insulin sensitivity and secretion in patients with type 2 diabetes. Bone. 2011;48(4):720–725.
17. 9. Chen X, Wu Y, Liu L, Tian H, Yu X. Osteocalcin is inversely associated with glucose levels in middle‐aged Tibetan men with different degrees of glucose tolerance. Diabetes Metab Res Rev. 2014;30(6):476–482.
18. 9. Chen X, Wu Y, Liu L, Tian H, Yu X. Osteocalcin is inversely associated with glucose levels in middle‐aged Tibetan men with different degrees of glucose tolerance. Diabetes Metab Res Rev. 2014;30(6):476–482.
19. 10. Onyenekwu CP, Azinge EC, Egbuagha EU, Okpara HC. Relationship between plasma osteocalcin, glycaemic control and components of metabolic syndrome in adult Nigerians with type 2 diabetes mellitus. Diabetes Metab Syndr Clin Res Rev. 2017;11(4):281–286.
20. 10. Onyenekwu CP, Azinge EC, Egbuagha EU, Okpara HC. Relationship between plasma osteocalcin, glycaemic control and components of metabolic syndrome in adult Nigerians with type 2 diabetes mellitus. Diabetes Metab Syndr Clin Res Rev. 2017;11(4):281–286.
21. 11. Hosseini S, Naderi-Manesh H, Vali H, Baghaban Eslaminejad M, Azam Sayahpour F, Sheibani S, Faghihi S. Contribution of osteocalcin-mimetic peptide enhances osteogenic activity and extracellular matrix mineralization of human osteoblast-like cells. Colloids Surf B Biointerfaces. 2019 Jan;173:662–671.
22. 11. Hosseini S, Naderi-Manesh H, Vali H, Baghaban Eslaminejad M, Azam Sayahpour F, Sheibani S, Faghihi S. Contribution of osteocalcin-mimetic peptide enhances osteogenic activity and extracellular matrix mineralization of human osteoblast-like cells. Colloids Surf B Biointerfaces. 2019 Jan;173:662–671.
23. 12. Sullivan TR, Duque G, Keech AC, Herrmann M. An old friend in a new light: the role of osteocalcin in energy metabolism. Cardiovasc Ther. 2013;31(2):65–75.
24. 12. Sullivan TR, Duque G, Keech AC, Herrmann M. An old friend in a new light: the role of osteocalcin in energy metabolism. Cardiovasc Ther. 2013;31(2):65–75.
25. 13. Guo Q, Li H, Xu L, Wu S, Sun H, Zhou B. Undercarboxylated osteocalcin reverts insulin resistance induced by endoplasmic reticulum stress in human umbilical vein endothelial cells. Sci Rep. 2017;7(1):1–9.
26. 13. Guo Q, Li H, Xu L, Wu S, Sun H, Zhou B. Undercarboxylated osteocalcin reverts insulin resistance induced by endoplasmic reticulum stress in human umbilical vein endothelial cells. Sci Rep. 2017;7(1):1–9.
27. 14. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg. 2014 Dec;12(12):1495–1499.
28. 14. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg. 2014 Dec;12(12):1495–1499.
29. 15. Faul F, Erdfelder E, Lang A-G, Buchner A. G*Power 3:A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;
30. 15. Faul F, Erdfelder E, Lang A-G, Buchner A. G*Power 3:A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;
31. 16. Hwang Y, Jeong I, Ahn KJ, Chung HY. The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced β‐cell function in middle‐aged male subjects. Diabetes Metab Res Rev. 2009;25(8):768–772.
32. 16. Hwang Y, Jeong I, Ahn KJ, Chung HY. The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced β‐cell function in middle‐aged male subjects. Diabetes Metab Res Rev. 2009;25(8):768–772.
33. 17. Terada M, Inaba M, Yano Y, Hasuma T, Nishizawa Y, Morii H, Otani S. Growth-inhibitory effect of a high glucose concentration on osteoblast-like cells. Bone. 1998;22(1):17–23.
34. 17. Terada M, Inaba M, Yano Y, Hasuma T, Nishizawa Y, Morii H, Otani S. Growth-inhibitory effect of a high glucose concentration on osteoblast-like cells. Bone. 1998;22(1):17–23.
35. 18. Zayzafoon M, Stell C, Irwin R, McCabe LR. Extracellular glucose influences osteoblast differentiation and c–jun expression. J Cell Biochem. 2000;79(2):301–310. 19. Karsenty G. Convergence between bone and energy homeostases: leptin regulation of bone mass. Cell Metab. 2006;4(5):341–348.
36. 18. Zayzafoon M, Stell C, Irwin R, McCabe LR. Extracellular glucose influences osteoblast differentiation and c–jun expression. J Cell Biochem. 2000;79(2):301–310. 19. Karsenty G. Convergence between bone and energy homeostases: leptin regulation of bone mass. Cell Metab. 2006;4(5):341–348.
37. 20. Aoki A, Muneyuki T, Yoshida M, Munakata H, Ishikawa S, Sugawara H, Kawakami M, Kakei M. Circulating osteocalcin is increased in early-stage diabetes. Diabetes Res Clin Pract. 2011;92(2):181–186.
38. 20. Aoki A, Muneyuki T, Yoshida M, Munakata H, Ishikawa S, Sugawara H, Kawakami M, Kakei M. Circulating osteocalcin is increased in early-stage diabetes. Diabetes Res Clin Pract. 2011;92(2):181–186.
39. 21. Winhofer Y, Handisurya A, Tura A, Bittighofer C, Klein K, Schneider B, Bieglmayer C, Wagner OF, Pacini G, Luger A, Willer AK. Osteocalcin is related to enhanced insulin secretion in gestational diabetes mellitus. Diabetes Care. 2010;33(1):139–143.
40. 21. Winhofer Y, Handisurya A, Tura A, Bittighofer C, Klein K, Schneider B, Bieglmayer C, Wagner OF, Pacini G, Luger A, Willer AK. Osteocalcin is related to enhanced insulin secretion in gestational diabetes mellitus. Diabetes Care. 2010;33(1):139–143.
41. 22. Hwang Y-C, Jee J-H, Jeong I-K, Ahn KJ, Chung HY, Lee M-K. Circulating osteocalcin level is not associated with incident type 2 diabetes in middle-aged male subjects: mean 8.4-year retrospective follow-up study. Diabetes Care. 2012;35(9):1919–1924.
42. 22. Hwang Y-C, Jee J-H, Jeong I-K, Ahn KJ, Chung HY, Lee M-K. Circulating osteocalcin level is not associated with incident type 2 diabetes in middle-aged male subjects: mean 8.4-year retrospective follow-up study. Diabetes Care. 2012;35(9):1919–1924.
43. 23. Lu C, Ivaska KK, Alen M, Wang Q, Törmäkangas T, Xu L, Wiklund P, Mikkola TM, Pekkala S, Tian H, Väänänen HK, Cheng S. Serum osteocalcin is not associated with glucose but is inversely associated with leptin across generations of nondiabetic women. J Clin Endocrinol Metab. 2012;97(11):4106–4114.
44. 23. Lu C, Ivaska KK, Alen M, Wang Q, Törmäkangas T, Xu L, Wiklund P, Mikkola TM, Pekkala S, Tian H, Väänänen HK, Cheng S. Serum osteocalcin is not associated with glucose but is inversely associated with leptin across generations of nondiabetic women. J Clin Endocrinol Metab. 2012;97(11):4106–4114.
45. 24. Colmorn LB, Petersen KB, Jakobsson M, Lindqvist PG, Klungsoyr K, Kallen K, Bjarnadottir RI, Tapper AM, Børdahl PE, Gottvall K, Thurn L, Gissler M, Krebs L, Langhoff-Roos J. The Nordic Obstetric Surveillance Study: a study of complete uterine rupture, abnormally invasive placenta, peripartum hysterectomy, and severe blood loss at delivery. Acta Obstet Gynecol Scand. 2015 Jul;94(7):734–744.
46. 24. Colmorn LB, Petersen KB, Jakobsson M, Lindqvist PG, Klungsoyr K, Kallen K, Bjarnadottir RI, Tapper AM, Børdahl PE, Gottvall K, Thurn L, Gissler M, Krebs L, Langhoff-Roos J. The Nordic Obstetric Surveillance Study: a study of complete uterine rupture, abnormally invasive placenta, peripartum hysterectomy, and severe blood loss at delivery. Acta Obstet Gynecol Scand. 2015 Jul;94(7):734–744.
47. 25. Díaz-López A, Bulló M, Juanola-Falgarona M, Martínez-González MA, Estruch R, Covas M-I, Arós F, Salas-Salvadó J. Reduced serum concentrations of carboxylated and undercarboxylated osteocalcin are associated with risk of developing type 2 diabetes mellitus in a high cardiovascular risk population: a nested case-control study. J Clin Endocrinol Metab. 2013;98(11):4524–4531.
48. 25. Díaz-López A, Bulló M, Juanola-Falgarona M, Martínez-González MA, Estruch R, Covas M-I, Arós F, Salas-Salvadó J. Reduced serum concentrations of carboxylated and undercarboxylated osteocalcin are associated with risk of developing type 2 diabetes mellitus in a high cardiovascular risk population: a nested case-control study. J Clin Endocrinol Metab. 2013;98(11):4524–4531.
49. 26. Caglar GS, Ozdemir ED, Kiseli M, Demirtas S, Cengiz SD. The association of osteocalcin and adiponectin with glucose metabolism in nondiabetic postmenopausal women. Gynecol Obstet Invest. 2014;77(4):255–260.
50. 26. Caglar GS, Ozdemir ED, Kiseli M, Demirtas S, Cengiz SD. The association of osteocalcin and adiponectin with glucose metabolism in nondiabetic postmenopausal women. Gynecol Obstet Invest. 2014;77(4):255–260.
51. 27. Kang JH. Association of serum osteocalcin with insulin resistance and coronary atherosclerosis. J bone Metab. 2016;23(4):183–190.
52. 27. Kang JH. Association of serum osteocalcin with insulin resistance and coronary atherosclerosis. J bone Metab. 2016;23(4):183–190.
53. 28. Im JA, Yu BP, Jeon JY, Kim SH. Relationship between osteocalcin and glucose metabolism in postmenopausal women. Clin Chim acta. 2008;396(1–2):66–69.
54. 28. Im JA, Yu BP, Jeon JY, Kim SH. Relationship between osteocalcin and glucose metabolism in postmenopausal women. Clin Chim acta. 2008;396(1–2):66–69.
55. 29. Lee SW, Jo HH, Kim MR, You YO, Kim JH. Association between obesity, metabolic risks and serum osteocalcin level in postmenopausal women. Gynecol Endocrinol. 2012;28(6):472–477.
56. 29. Lee SW, Jo HH, Kim MR, You YO, Kim JH. Association between obesity, metabolic risks and serum osteocalcin level in postmenopausal women. Gynecol Endocrinol. 2012;28(6):472–477.
57. 30. Bulló M, Moreno-Navarrete JM, Fernández-Real JM, Salas-Salvadó J. Total and undercarboxylated osteocalcin predict changes in insulin sensitivity and β cell function in elderly men at high cardiovascular risk. Am J Clin Nutr. 2012;95(1):249–255.
58. 30. Bulló M, Moreno-Navarrete JM, Fernández-Real JM, Salas-Salvadó J. Total and undercarboxylated osteocalcin predict changes in insulin sensitivity and β cell function in elderly men at high cardiovascular risk. Am J Clin Nutr. 2012;95(1):249–255.
59. 31. Kajimura D, Lee HW, Riley KJ, Arteaga-Solis E, Ferron M, Zhou B, Clarke CJ, Hannun YA, DePinho RA, Guo XE, Mann JJ, Karsenty G. Adiponectin regulates bone mass via opposite central and peripheral mechanisms through FoxO1. Cell Metab. 2013;17(6):901–915.
60. 31. Kajimura D, Lee HW, Riley KJ, Arteaga-Solis E, Ferron M, Zhou B, Clarke CJ, Hannun YA, DePinho RA, Guo XE, Mann JJ, Karsenty G. Adiponectin regulates bone mass via opposite central and peripheral mechanisms through FoxO1. Cell Metab. 2013;17(6):901–915.
61. 32. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7(8):941–946.
62. 32. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7(8):941–946.
63. 33. Pittas AG, Harris SS, Eliades M, Stark P, Dawson-Hughes B. Association between serum osteocalcin and markers of metabolic phenotype. J Clin Endocrinol Metab. 2009;94(3):827–832.
64. 33. Pittas AG, Harris SS, Eliades M, Stark P, Dawson-Hughes B. Association between serum osteocalcin and markers of metabolic phenotype. J Clin Endocrinol Metab. 2009;94(3):827–832.
65. 34. Gundberg CM, Looker AC, Nieman SD, Calvo MS. Patterns of osteocalcin and bone specific alkaline phosphatase by age, gender, and race or ethnicity. Bone. 2002;31(6):703–708.
66. 34. Gundberg CM, Looker AC, Nieman SD, Calvo MS. Patterns of osteocalcin and bone specific alkaline phosphatase by age, gender, and race or ethnicity. Bone. 2002;31(6):703–708.
67. 35. Lucey AJ, Paschos GK, Thorsdottir I, Martínéz JA, Cashman KD, Kiely M. Young overweight and obese women with lower circulating osteocalcin concentrations exhibit higher insulin resistance and concentrations of C-reactive protein. Nutr Res. 2013;33(1):67–75.
68. 35. Lucey AJ, Paschos GK, Thorsdottir I, Martínéz JA, Cashman KD, Kiely M. Young overweight and obese women with lower circulating osteocalcin concentrations exhibit higher insulin resistance and concentrations of C-reactive protein. Nutr Res. 2013;33(1):67–75.